Endpoint
Mitral E/e' ratio
CAT:outcome/mitral-e-to-e-prime-ratioreported in ratio1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| spironolactone | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
1 finding
spironolactone — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Spironolactone reduced LAVi by -1.1 (-2.0 to -0.1) ml/m2 (p = 0.03); LVMi by -3.6 (-6.4 to -0.8) g/m2 (p = 0.01); IVS thickness by -0.2 (-0.3 to -0.1) mm (p = 0.01); E/e' ratio by -1.3 (-2.4 to -0.2) (p = 0.02); and increased LVEF by 1.7 (0.8-2.6)% (p < 0.01).”
Quoted verbatim from Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.. - Study
- meta-analysis
- Population
- Patients with stage B or C heart failure with preserved ejection fraction, individual-patient-data pooling of HOMAGE, Aldo-DHF and TOPCAT; spironolactone versus placebo or control, 9-12 month exposure
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.2023PMID:36303266Permalink
How it is measured
Ratio of early diastolic mitral inflow velocity (E) to early diastolic mitral annular tissue Doppler velocity (e') by transthoracic echocardiography, an index of left ventricular filling pressure. Septal, lateral or averaged e' is recorded with each finding.
Sources cited
1 paper
- Subject
- mitral e/e' ratio
- Findings
- 1
- Papers
- 1